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Abstract: The adjuvant activity of liposomes coated with mannan-cholesterol was studied
in mice. Ovalbumin (OVA) was reconstituted into liposomes as a model antigen. The ad-
juvant activity was assessed by the following two immunological responses: delayed-type
hypersensitivity (DTH) footpad swelling responses and in vitro release of interferon-γ and
interleukin-4 by regional lymph node cells. First, we studied dose effects on DTH responses
of total lipid, mannan-cholesterol and OVA used for liposomes. The minimal doses per
mouse required for the induction of optimal responses were as follows; 1μg of OVA, 10μg of
mannan-cholesterol and 336μg of total lipid. Second, immunological and histopathological
studies showed the following two points: 1) mannan-coated liposomes induced a tuberculin-
type DTH response while non-coated liposomes elicited a Jones-Mote reaction, and 2) man-
nan-coated liposomes induced obvious microabscesses but non-coated liposome did not.
Third, the inoculation of mannan-coated liposomes rendered the regional lymph node cells to
release a large amount of interferon-γ with little IL-4 against OVA while non-coated lipo-
some released neither of the lymphokines. These results indicated that mannan-coated lipo-
somes are a potent adjuvant to induce type 1 helper T cells but have a disadvantage to form
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adjuvants such as being biodegradable, non-toxic and non-immunogenic (Gregoriadis, 1995). They
also have the advantage of being able to induce cell-mediated immunity: Noguchi et al (1991)
reported that liposomes coated with yeast mannan induced a cytotoxic T-cell (CTL) response
against a virus-related protein reconstituted in them. In the present experiment, we investigated
the characteristics of liposome adjuvant coated with mannan in detail, and evaluated their
potential as adjuvant･ Liposomes reconstituted with ovalbumin (OVA) as a model antigen were
used, and their immunogenicity in mice to induce a DTH footpad swelling response and in vitro
release of lymphokines by regional lymph node cells was assessed in mice. Part of preliminary
results of the present investigation is reported previously (Sugimoto et οlリ1995).
MATERIALS AND METHODS
〟ice: 6-week old female inbred Balb/c mice were obtained from Charles River Japan, Inc…
(Yokohama), and were used at the ages of 7-to 12-week old.
Reagents: Dipalmitoylphosphatidylcholine (DPPC) and cholesterol were purchased from
Nichiyu Liposome Co. Ltd. (Tokyo)… OVA and mannan-cholesterol (Cholesterol-AECM Mannan)
were obtained from Wako Purechem. Inc. Ltd. (Osaka) and Dojin Laboratories (Kumamoto),
respectively.
Preparation of liposomes: Liposomes (multilamellar vesicles) reconstituted with OVA were
prepared according to the modified method by Bangham et al. (1965): 5(%1 of lOmM DPPC in
chloroform-methanol (2:1) solution and 250//1 of lOmM cholesterol in the same solvent were mixed
in a conical flask, and then the organic solvent was removed by evaporation… 200μl of lO喝/ml
OVA solution was added to the dried lipid film, and then multilamellar vesicles were prepared by
vortex dispersion. The amount of OVA in the liposomes was determined by BCA protein assay
reagent (Pierce, Rockford IL) after dissolution in 2% sodium dodecylsulfate solution at a boiling
temperature. Liposomes were coated with mannan-cholesterol by incubating liposomes overnight
with mannanヾholesterol solution at 4℃. More than 95% of mannan-cholesterol was adsorbed to
liposomes. The amounts of cholesterol and carbohydrate were determined by the assay kit of
Cholesterol CII Test (Wako Purechem. Inc., Ltd.), and anthrone-sulfate method, respectively.
The total lipid of liposomes was calculated from the amount of cholesterol (the ratio of DPPC and
cholesterol was 2:1 in mole ratio).
Immunological assays: A DTH response was assessed by footpad swelling response as fol-
lows (Sugimoto et al., 1995): Mice were immunized subcutaneously at two sites on the dorsal skin
on day 0 with liposomes suspended in 200μ1 of phosphate buffered saline (PBS). Unless otherwise
mentioned, mice were immunized with liposοmes with the following doses of each component per
mouse; 5-10μg of OVA, 50-100μg of mannan-cholesterol and about 350μg of total lipid. At various
days after immunization, they were challenged subcutaneously in the right hind footpad with lOμg
OVA with 25μg alum adjuvant in 25μ1 PBS and in the left footpad with the same solution without
OVA as a control. The specific footpad swelling responses were expressed as the difference be-
tween the thickness of right and left footpad… Footpad thickness was measured by a Peacock dial
thickness gauge (Osaki MGF Inc., Ltd., Tokyo). Unless otherwise mentioned, the footpad
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swelling response was assayed 24 hours after the challenge in the footpad. Usually 5 animals were
used in each gorup.
IFN-r and IL-4 assays: The release of IFN-?- and IL-4 in vitro was assayed as follows: On day
o, two groups of mice were immunized subcutaneously in both footpads with mannan-coated or
non-coated liposome, and on day 7 they received an additional immunization with the same an-
tigen. On day ll, popliteal lymph nodes of right and left hind legs were removed. Cell suspensions
of lymph node cells were made, and cultured with a 96-well plate (5 × 105 cells/100μ1/well) in
RPMI1640 medium containing lO% fetal calf serum with or without OVA at 37℃ for 3 days. The
amount of IFN-?- or IL-4 released in the culture medium was determined using a kit for mouse
IFN-7 (Genzyme, Cambridge, MA), or a kit for mouse Iし4 (Endogen lnc., Boston, MA),
respectively.
Histopathological observation: Specimens of the skin of footpad challenged with OVA and
back skin inoculated with various liposomes were fixed in lO% formalin and their paraffin sections
were prepared by conventional methods. They were stained with haematoxylin and eosin, and
were observed under a light microscope.
RESULTS
The time courses of DTH responses: Previously we reported that mannan-coated liposomes
(+ OVA) induced a strong footpad swelling response in mice with a peak at 24 to 48 hours after
challenge with OVA, whereas non-coated liposomes ( + OVA) induced a weak response at 12 hours
after challenge (3, see also Fig. 1). Fig. 2 shows the time courses of 12-hour and 24-hour responses
induced by non-coated liposomes as well as mannan-coated liposomes･ The 24-hour response with
mannancoated liposomes continued to increase toward 18 days after immunization whereas the
12-hour response with non-coated liposomes had a peak 7 days after immunization and tended to
decrease thereafter. These results together support the idea that the 24-hour response with
mannan-coated liposomes is a tuberculin-type DTK reaction while the 12-hour response with
non-coated liposome is a Jones-Mote reaction (Klein, 1982).
Dose effects ofmannan-cholesterol, ο VA and total lipid: When the dose of mannan-cholesterol
was changed while the doses of OVA and lipid being fixed at 3.9 and 336jォg/mouse respectively,
a maximal response was attained at lOμg/mouse of mannan-cholesterol or above (Fig. 3). For the
dose effect of OVA with fixed doses of total lipid and mannan-cholesterο1, nearly plateau levels of
responses were attained at 0.9μg/mouse or above. Under the conditions by fixing the dose of OVA
at lOμg/mouse, the increase of total lipid content of liposomes from 29 to 326μg/mouse led to
dose-dependent augmentation of the footpad response. A near plateau level was attained at total
lipid contents above 326μg/mouse (data not shown). It is noted that the effect of coating with
mannan-cholesterol was much more obvious at the higher lipid contents.
Histological observation: The histological profile of the footpad swelling responses was in-
vestigated, and summarized in Table 1. The skin lesions of 24- and 48-hour responses by man-

















































































































































Fig. 4. Histopatnological studies of the footpad skin and back skin. Mice were immunized with man-
nan-coated liposomes with OVA, and 7 days after immunization right footpad was challenged
with OVA in alum adjuvant (a), while the left footpad was challenged with alum adjuvant alone
(b). Infiltration with raononuclear cells is obvious in the dermis and loose connective tissue of
the right footpad, but they are absent in the left footpad. The back skin inoculated with man-
nan-coated liposomes with OVA 9 days previously formed a microabscess (c). Part of the
microabscess is seen in the right/bottom corner with nuclear debris mixed with mononuclear
cells and polymorphonuclear cells. There are many mononuclear cells and fibroblast cells sur-
rounding the microabscess. Stained with haematoxylm and eosme. A and B, x40; C, x!6.
polymorphonuclear cells (Fig. 4a). The 12-hour response lesion of non-coated liposomes, on the
other hand, was characterized by mild infiltration by polymorphonuclear leukocytes with a rela-
tively small number of mononuclear cells (data not shown). These results support the conclusion
as mentioned above that the 24- and 48-hours responses with mannan-coated liposomes are a
tuberculin-type DTH response whereas the 12-hour response with non-coated liposomes is a
Jones-Mote reaction. The lesion of the back skin inoculated with hposomes was also investigated.
Sometimes obvious microabscesses were formed at the sites inoculated with mannan-coated
liposomes. There were numerous aggregates of nuclear debris inside the microabscess (Fig. 4c)･
Most of these materials seemed to be derived from leukocytes since many monomiclear cells and
polymorphonuclear cells were seen in it. There were many mononuclear cells as well as fibro-
blast-like cells around the tissue of the microabscess. The size of microabscesses varied
depending on individual animals of the same group, and even between two inoculation sites on the
back skin of the same animal. Non…coated liposomes rarely formed obvious microabscesses･
In vitroわ′mphokine release responses: In vitro release of both IFN-?- and IL-4 by OVA
stimulation was assessed for the regional lymph node cells obtained from mice immunized with
mannan-coated liposomes (+ OVA) as well non-coated liposomes (+OVA). The lymph node cells
of mice immunized with mannan-coated liposomes released a large amount of IFN…f with
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Non－C。ated　　　　　　＜0－l　　　＜0－l　　　＜0．1　　＜0－0l　　　　＜0．Ol
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DISCUSSIOM
Thepresentresu1tsindicatedthatmannan－COatedliposomesrecOnStitutedwithOVAin－
ducedastrongtubercu1in－tyPeDTHresponsesaccompaniedbyre1easeOfIFM－γbyreg10na1
1ymphnodece11sagainstOVAstimu1ation．Fromtheseresultst0getherwiththefactthatman．
nan－COated1ipOSOmesinducedCTLresponsesagainsttheantigensrecOnStitutedintOthem
（Noguchietal．，1991；Ohishietal．，1996），itisconc1udedthatmannan－COated1ipOsOmeSarepOtent
stimu1atorfortypelhe1perT．ce11s．Recent1y，a1argebody0fevidenceisaccumu1atingthat
Ce11－mediatedimmunityp1aysanpivota1ro1einthepreventionfrominfectiousdiseasesby
retr0ViruSeSSuChashumanimmunodeficiencyvirus（HIV）（Sa1ketal．，1993）andbovine1eukemia
Virus（BLV）（Ohishietal．，1991；SugimOtOetal．，1993）－Thesefactsraisethep0ssibilitythat
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mannan－COated1iposomesareusab1easadjuvantagainsttheseinfectiousdiseaSeS．Inthiscon－
nection，itisa1soWOrthhWhi1etonotethat1ipOSOmeSCOatedwithoiigosaccharidesinducenatura1
ki11erce11s（Bezouskaetal．，1994）．Thus，mannan－C0ated1iposomesmayalsOstimu1ateinnate
immunitytogetherwiththeaugmentationofimmunityspecifictotheantigenreconstitutedinit．
ThedOseeffectsofthecomponentsofmannan－COated1iposomesindicatedminima1doses
fortheinductionofoptima1responses．Practica11y，thesedataareimportant，sinceassma1idoses
aspossib1earerequiredfromaneconomica1standpointaswe11astoreducesideeffectssuchas
thefOrmationofmicr0abscesses，asdiscusSednext．
Onepotentia1prob1emmaybetheformatiOnOfmicroabscesses（Fig．4c）．Thisprocess
SeemstObecomposedoftheinfi1tratiOnOf1euk0CyteSfo110wedbyformationofasmal1granu10ma．
Todea1withthisprOb1em，thef0110Wingthingsareconsidered．1）Sincenon－COated1iposomesdid
notformobviousmicrOabscesses，thereducti0nOftheamOunt0fmannan－Cho1estero1tothe1eve1s
assma11aspossib1emaybeeffective．2）Fr0mthefactthatmodeofmicroabscessformationvaried
dependingonindividua1anima1sasWe11asOninocu1ationsites，itmaybethatchOice0fthein－
OCu1ationsitesorofthedepthofsubcutaneousinjecti0nreducesthesideeffect．3）Theuseof
O1igomannosesinsteadOfmannanmaya1sObeeffective（SugimOtOetal．，1995）．
Asfortheeffectivenessoftheadjuvantactivityofmannan．coated1iposomes，theiras－
sessmentinanima1infectiousdiseasemode1sisessentia1．
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